Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Rodman & Renshaw Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces Price Target of $16

Author: Benzinga Newsdesk | August 22, 2024 01:28pm
Rodman & Renshaw initiates coverage on Emergent BioSolutions (NYSE:EBS) with a Buy rating and announces Price Target of $16.

Posted In: EBS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist